Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3

Conditions: HER2+ Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pyrotinib
Drug: Anti-PD-1 monoclonal antibody
Drug: CDK4/6 inhibitor
Drug: Pertuzumab
Drug: Capecitabine
Drug: Nab paclitaxel
Drug: AI
Drug: T-DM1
Drug: Everolimus

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 120

Registration Number: NCT05429684

Locations: 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
Jin Yang, Xi'an, Shaanxi, China

FOLFIRINOX + NIS793 in Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreas Cancer
Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: FOLFIRINOX
Drug: NIS793
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Irinotecan
Drug: 5-Fluorouracil (5-FU)
Radiation: Chemoradiation
Radiation: Radiation Therapy
Drug: Capecitabine
Procedure: Surgery

First Posted Date: 2022-06-14

Last Posted Date: 2024-06-25

Lead Sponsor: Colin D. Weekes, M.D., PhD

Target Recruit Count: 4

Registration Number: NCT05417386

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Phase 1

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: Accelerated Radiation Therapy
Radiation: Intensity-modulated radiation therapy
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2022-06-09

Last Posted Date: 2023-10-02

Lead Sponsor: University of Miami

Target Recruit Count: 25

Registration Number: NCT05412082

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat
Drug: Capecitabine
Drug: Endocrine Therapy

First Posted Date: 2022-06-09

Last Posted Date: 2022-11-04

Lead Sponsor: wang shusen

Target Recruit Count: 73

Registration Number: NCT05411380

Locations: 🇨🇳
Shusen Wang, Guangzhou, Gangdong, China

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Capecitabine
Drug: Tucidinostat

First Posted Date: 2022-05-25

Last Posted Date: 2022-11-04

Lead Sponsor: wang shusen

Target Recruit Count: 126

Registration Number: NCT05390476

Locations: 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Guangdong, China

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Phase 3

Recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: 177Lu-DOTATOC
Drug: Capecitabine

First Posted Date: 2022-05-24

Last Posted Date: 2024-08-20

Lead Sponsor: Lund University Hospital

Target Recruit Count: 300

Registration Number: NCT05387603

Locations: 🇸🇪
Sahlgrenska University Hospital, Dept. of Oncology, Göteborg, Sweden
🇸🇪
Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden
🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden

and more 1 locations